TY - JOUR
T1 - Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population
T2 - Results from the Dutch Castration-resistant Prostate Cancer Registry
AU - Notohardjo, Jessica C.L.
AU - Kuppen, Malou C.P.
AU - Westgeest, Hans M.
AU - van Moorselaar, Reindert J.A.
AU - Mehra, Niven
AU - Coenen, Jules L.L.M.
AU - van Oort, Inge M.
AU - de Vos, Aad I.
AU - Vervenne, Walter L.
AU - van den Bergh, Alphons C.M.
AU - Aben, Katja K.H.
AU - Somford, Diederik M.
AU - Bergman, Andries M.
AU - Uyl-de Groot, Carin A.
AU - Gerritsen, Winald R.
AU - van den Eertwegh, Alfons J.M.
N1 - Funding Information:
This research was funded by Sanofi-AventisNetherlands B.V., Janssen-Cilag B.V., Astellas Pharma B.V., and Bayer B.V. The funding organisations had no role in the design and conduct of thestudy; collection, management, analysis, and interpretation of the data;and preparation, review, or approval of the manuscript.
Publisher Copyright:
© 2020 European Association of Urology
PY - 2020/4/30
Y1 - 2020/4/30
N2 - Third-line life-prolonging drugs (LPDs) might not be appropriate for all metastatic castration-resistant prostate cancer patients. We developed a prognostic model and identified a high-risk subgroup in which no meaningful benefit from third-line LPDs is derived in clinical practice.
AB - Third-line life-prolonging drugs (LPDs) might not be appropriate for all metastatic castration-resistant prostate cancer patients. We developed a prognostic model and identified a high-risk subgroup in which no meaningful benefit from third-line LPDs is derived in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85084140393&partnerID=8YFLogxK
U2 - 10.1016/j.euf.2020.03.009
DO - 10.1016/j.euf.2020.03.009
M3 - Article
C2 - 32362484
AN - SCOPUS:85084140393
SN - 2405-4569
JO - European Urology Focus
JF - European Urology Focus
ER -
